FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
Listen to an audio podcast of the February 13 2020 FDA Drug Safety Communicationrequesting the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Potential risk of cancer outweighs the benefits.
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Podcasts | Weight Loss